A medication that functions similarly to Viagra has demonstrated the ability to slow the progression of Alzheimer’s disease by nearly a third, according to a new global study. The findings, presented at the Clinical Trials on Alzheimer’s Disease conference in Boston, offer a fresh perspective on treating the most common form of dementia.
AR1001, developed by the South Korean company AriBio, belongs to a class of drugs known as phosphodiesterase-5 inhibitors. This is the same family of medicines used to treat erectile dysfunction. Unlike existing treatments that target amyloid proteins in the brain, AR1001 works by relaxing blood vessels to increase blood flow to the brain.
AR1001 Trial Results in Early Patients
The stage three trial involved 604 participants with early-stage Alzheimer’s disease who were not taking any other medications for the condition. Researchers found that the tablet slowed cognitive decline by 31% over the course of the study. The side effects reported by these participants were mostly mild to moderate.
However, the drug did not show statistically significant benefits in a wider group of patients who were already taking other Alzheimer’s medications. This discrepancy suggests that the treatment’s effectiveness may depend on whether patients are receiving concurrent therapies, a point that requires further investigation.

Professor Tara Spires-Jones of the University of Edinburgh, who was not involved in the study, noted that the drug likely works by boosting blood flow and stimulating pathways in brain cells that support learning and memory. She described the results as very promising.
Expert Reaction to New Approach
Independent experts have welcomed the findings as a significant step forward in dementia research. Dr. Sheona Scales, director of research at Alzheimer’s Research UK, called the results very encouraging. She highlighted that AR1001 takes a different approach by acting on a specific enzyme rather than targeting amyloid, which has been the primary focus of many previous treatments.
Dr. Richard Oakley, associate director of research and innovation at the Alzheimer’s Society, described the topline results as an exciting sign. He emphasized that the drug tackles the causes of the disease rather than just the symptoms. Oakley also noted that the once-daily tablet format could make treatment simpler for patients compared to other disease-modifying therapies.

Despite the positive data, experts urged caution. The drug must undergo rigorous scrutiny by regulatory bodies and the wider scientific community before it can be prescribed. Oakley specifically warned against people taking Viagra to treat Alzheimer’s, noting that AR1001 is being developed specifically for this condition and is not a substitute.
Alzheimer’s disease is projected to affect 153 million people worldwide by 2050. With no current cure, the search for effective interventions remains a global priority. This trial represents one of the few recent instances where a drug has shown a substantial slowing of clinical decline in early-stage patients.
The next steps involve further trials to understand why the drug was less effective in patients taking other medications. Regulatory approval will depend on the outcomes of these additional studies and the review of safety data by health authorities.
Source: The Guardian

